DCC 1 Sevlievo EOOD
Welcome,         Profile    Billing    Logout  
 2 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moreno, Jose C
NCT04740671 / 2020-005364-57: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Active, not recruiting
3
388
Europe, US, RoW
HLX04-O, ranibizumab
Shanghai Henlius Biotech
Age Related Macular Degeneration
12/24
03/25
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Jul 2024 - Sep 2024 : Data for CLE
Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
12/24
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Active, not recruiting
2
159
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
07/25
07/25
NCT05032196: Study of WVE-003 in Patients With Huntington's Disease

Completed
1/2
47
Europe, Canada, RoW
WVE-003
Wave Life Sciences Ltd.
Huntington Disease
05/24
05/24
CHARTER, NCT05437679: Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Terminated
N/A
9
US
Blood collection, Data collection
Angle plc, MidLantic Urology, LLC
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
08/23
08/23
Testa, Gladys Alicia
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Jul 2024 - Sep 2024 : Data for CLE
Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
12/24
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis Pain

Active, not recruiting
2
263
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain, Osteoarthritis, Knee
08/24
11/24
Nikolov, Dimitar
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Jul 2024 - Sep 2024 : Data for CLE
Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
12/24
NCT05864560: Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up

Recruiting
N/A
162
Europe, RoW
Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System
Lifetech Scientific (Shenzhen) Co., Ltd.
Abdominal Aortic Aneurysm
03/26
12/27

Download Options